67593-29-7

Basic information

• Product Name: 3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-5-cyano-1,4-dihydro-2,6-dimethyl-, methyl ester
• CAS NO: 67593-29-7
• Molecular Formula: C16H15ClN2O2
• Molecular Weight: 302.76
• Mol File: 67593-29-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-5-cyano-1,4-dihydro-2,6-dimethyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-5-cyano-1,4-dihydro-2,6-dimethyl-, methyl ester(67593-29-7)
• EPA Substance Registry System: 3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-5-cyano-1,4-dihydro-2,6-dimethyl-, methyl ester(67593-29-7)

Safety Data

• Hazardous Substances Data: 67593-29-7(Hazardous Substances Data)

Upstream product

• 1118-61-2 3-Aminocrotononitrile 
• 67593-46-8 methyl 2-(2-chlorophenylmethylene)acetoacetate 

Downstream Products

• 845743-68-2 methyl 2-{[(2-{[(2S)-3-(2-cyanophenoxy)-2-hydroxypropyl]amino}-2-methylpropyl)amino]methyl}-4-(2-chlorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate 
• 845744-10-7 methyl 2-[({2-[(tert-butoxy)carbonylamino]-2-methylpropyl}amino)methyl]-4-(2-chlorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate 
• 845744-11-8 methyl 2-{[(2-amino-3-methylpropyl)amino]methyl}-4-(2-chlorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate 
• 845744-09-4 methyl 2-(bromomethyl)-4-(2-chlorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate 

Relevant articles and documents

Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists

A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.